{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar",
    "query": {
      "intervention": "Gemzar"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1615,
    "total_pages": 162,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T01:42:57.381Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07144254",
      "title": "Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteosarcoma Recurrent",
        "Osteosarcoma in Children",
        "Relapsed Osteosarcoma",
        "Refractory Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-01-22",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07144254"
    },
    {
      "nct_id": "NCT03391466",
      "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum-containing Salvage Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 359,
      "start_date": "2018-01-25",
      "completion_date": "2024-11-25",
      "has_results": true,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03391466"
    },
    {
      "nct_id": "NCT00783172",
      "title": "Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Opioid Growth Factor (OGF)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2009-01",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 2,
      "location_summary": "Allentown, Pennsylvania • Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00783172"
    },
    {
      "nct_id": "NCT01663285",
      "title": "Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant Cisplatin and Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2012-09",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 3,
      "location_summary": "Ann Arbor, Michigan • Rochester, New York • Portland, Oregon",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01663285"
    },
    {
      "nct_id": "NCT00714948",
      "title": "Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "URINARY BLADDER"
      ],
      "interventions": [
        {
          "name": "gemcitabine and cisplatin plus sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2008-07",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2015-11-16",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00714948"
    },
    {
      "nct_id": "NCT07129993",
      "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Urothelial Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 630,
      "start_date": "2025-09-26",
      "completion_date": "2030-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 38,
      "location_summary": "Fullerton, California • Glendale, California • La Jolla, California + 34 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07129993"
    },
    {
      "nct_id": "NCT05241249",
      "title": "Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "Bethanechol",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Susan E. Bates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2022-02-01",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241249"
    },
    {
      "nct_id": "NCT00336648",
      "title": "Preop Chemoradiation Resectable Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Avastin (Bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2006-06",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336648"
    },
    {
      "nct_id": "NCT01270724",
      "title": "Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CNS Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2010-08",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01270724"
    },
    {
      "nct_id": "NCT04299880",
      "title": "Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oncology"
      ],
      "interventions": [
        {
          "name": "Napabucasin",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2020-02-24",
      "completion_date": "2021-05-30",
      "has_results": false,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-09-05T01:42:57.381Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Scarborough, Maine • Portland, Oregon",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04299880"
    }
  ]
}